" class="no-js "lang="en-US"> Non-invasive Imaging in Gastrointestinal Tumors Results Published
Friday, March 31, 2023

Results of CLDN18.2-targeting Immuno-PET Probe for Non-invasive Imaging in Gastrointestinal Tumors Published

Transcenta, a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that the study results of its CLDN18.2-targeting Immuno-PET probe [89Zr]Zr-DFO-TST001 for non-invasive imaging in gastrointestinal tumors have been published on Journal of Pharmaceutical Analysis.

The study, led by Professor Hua Zhu and his team from Beijing Cancer Hospital. The study successfully prepared and evaluated the 89Zr labeled GMP grade anti-CLDN18.2 recombinant humanized antibody TST001 as molecular imaging probe. [89Zr]Zr-DFO-TST001 exhibited good specificity at the cellular level and rapid tumor accumulation which remained positive from 24 to 96 hours. It provides a promising non-invasive imaging tool for detecting the treatment effects of therapeutic antibodies in humans in real time and for the screening and efficacy evaluation of patients targeted for CLDN18.2 therapy in the future.

Clinical studies indicated that the CLDN18.2 expression level was correlated with drug efficacy, showing more clinical benefit in patients with CLDN18.2 high expression in tumors. Therefore, patient selection based on CLDN18.2 expression level becomes critical for CLDN18.2-targeted therapies. At present, the main detection method of CLDN18.2 protein expression is immunohistochemistry (IHC). IHC is invasive, and requires endoscopic biopsy, and the sampling site and number are limited. Due to the heterogeneous nature of tumor, the CLDN18.2 distribution and dynamic changes in expression levels in patients cannot be fully reflected in real-time. Molecular imaging can be used as a non-invasive diagnostic tool to detect the expression and distribution of CLDN18.2 in the lesion using the radioactive signal emitted by the radiotracer, thereby help to screen patients with potential benefit to therapy, evaluate the efficacy of CLDN18.2 targeted therapy, and guide the accurate diagnosis and treatment of tumors.

“This study successfully achieved the development, quality control and Micro-PET imaging clinical evaluation of GMP-grade monoclonal nuclide probes targeting CLDN18.2, providing a new path for the development of ZR-89-labeled tumor targeting monoclonal antibodies. In cell and animal models, [89Zr]Zr-DFO-TST001 specifically recognizes and targets the CLDN18.2 receptor/tissue. With the increasingly popular PET/CT examination equipment, the probe is expected to be used for screening patients with potential benefit to therapy, localizing of systemic lesions and efficacy evaluation,” said Prof. Hua Zhu from Beijing Cancer Hospital.

“We are fortunate to have the opportunity to collaborate with leading colleges and institutes on the development of a CLDN18.2-targeting Immuno-PET Probe for gastrointestinal tumors. Optimizing the selection of patients in a non-invasive way is key to improve the overall benefit risk of CLDN18.2 targeted treatments. This technology also opens up innovative ways of monitoring treatment outcomes. We look forward to further development of this approach and potential use in the clinics,” said Dr. Xueming Qian, CEO of Transcenta.

Companies In This Post

  1. Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions Read more
  2. Sensorion Appoints Khalil Barrage as Interim Chairman of the Board Read more
  3. Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China Read more
  4. Hansa Biopharma Completes Enrollment in Phase 2 Study of Imlifidase in Guillain-Barré Syndrome (GBS) Read more
  5. ProJenX Announces Formation of Scientific Advisory Board for Development of ALS Treatment Read more